Related Experiment Video
Updated: Jun 7, 2026

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
[Immunocorrecting therapy of chronic bacterial prostatitis]
Abstract:
A total of 55 patients aged 20-59 years with recurrent chronic bacterial prostatitis (RCBP) entered a trial of immunomodulator panavir. The study group consisted of 40 patients. They were given standard treatment and panavir. The control group (n = 15) matched by all the studied characteristics received standard treatment only. Blood count, bacteriological characteristics of prostatic secretion, immunological status, subjective parameters were studied. RCBP patients were diagnosed to have marked disorders of interferon status. The addition of panavir to standard treatment of RCBP patients significantly improved treatment results. Therefore, panavir is recommended as an adjuvant in combined RCBP treatment.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Trichomoniasis
Tumor Immunotherapy
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection II: Pathophysiology
Urinary Tract Infection IV: Nursing Management
